Topic: Health
Scientists at the University at Buffalo have developed a new injectable gel that can keep osteoarthritis treatments inside the joint for several weeks. This could reduce the need for frequent injections and lower the risk of side effects. The gel is made up of a biocompatible polymer matrix with drug-loaded nanocarriers.
A team of scientists at the University at Buffalo has created an injectable hydrogel that can keep osteoarthritis treatments inside the joint for much longer than conventional injections.
Osteoarthritis (OA) is one of the world's leading causes of chronic pain and disability. Common treatments delivered directly into joints, including analgesics, corticosteroids, and viscosupplements, can ease symptoms, but their effects are often short-lived. The biggest obstacle in treating OA is that small molecule drugs and biologics can be cleared quickly from synovial fluid.
The University at Buffalo hydrogel platform was designed to address both problems by keeping therapeutic compounds concentrated in the joint and releasing them gradually over time. The injectable formulation begins as a liquid, allowing it to be delivered with a minimally invasive procedure. At body temperature, it rapidly becomes a lubricious semisolid material that acts as a local drug reservoir.
The platform combines a biocompatible polymer matrix with drug-loaded nanocarriers. These nanocarriers are designed to carry high amounts of poorly soluble therapeutic compounds, which are otherwise difficult to deliver in an aqueous environment. The system also uses materials with prior regulatory acceptance, making eventual clinical translation more practical.
Once inside the joint, therapeutic compounds are released through diffusion and gradual relaxation of the hydrogel matrix. This process provides controlled local exposure over multiple weeks rather than allowing the medication to disappear rapidly from the joint.
Why It Matters
This breakthrough could have a significant impact on the lives of millions of people suffering from osteoarthritis in India, where the disease is becoming increasingly common due to lifestyle changes and aging population. If successful, this technology could reduce the need for frequent injections and lower the risk of side effects, improving the quality of life for patients.
Key Facts
- Scientists at the University at Buffalo have developed an injectable hydrogel that can keep osteoarthritis treatments inside the joint for several weeks.
- The gel is made up of a biocompatible polymer matrix with drug-loaded nanocarriers.
- Osteoarthritis (OA) is one of the world's leading causes of chronic pain and disability.
- Common treatments delivered directly into joints can ease symptoms, but their effects are often short-lived.
- The University at Buffalo hydrogel platform was designed to address both problems by keeping therapeutic compounds concentrated in the joint and releasing them gradually over time.
Key Terms
- Osteoarthritis
- A type of arthritis that causes chronic pain and disability due to wear and tear on joints.
- Hydrogel
- A gel-like substance made up of a biocompatible polymer matrix with drug-loaded nanocarriers.
Implications
This breakthrough could have a significant impact on the lives of millions of people suffering from osteoarthritis in India, where the disease is becoming increasingly common due to lifestyle changes and aging population. If successful, this technology could reduce the need for frequent injections and lower the risk of side effects, improving the quality of life for patients.
Leave a comment